Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Dr Colin Brown, the most common co-covered peer. The tracked stories average 2 original sources each. NHS Blood and Transplant (NHSBT) appears in 1 tracked Biotech story from August 17, 2026.
Last mentioned: 6d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Dr Colin Brown, the most common co-covered peer. The tracked stories average 2 original sources each. NHS Blood and Transplant (NHSBT) appears in 1 tracked Biotech story from August 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NHS Blood and Transplant (NHSBT). Shared-story counts are live from our verified record — not editorial picks.
The NHS's £1.37M double match programme applies closer HLA matching between blood donors and kidney transplant recipients to reduce alloantibody-mediated rejection. Around two in five kidney transplant patients need transfusion and can develop HLA antibodies, a known driver of organ rejection, and the rollout targets 100 fewer rejections per year.
Source: aol.co.uk · mirror.co.uk
NHS Blood and Transplant (NHSBT) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
